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P eroxidasin is an animal heme peroxidase withbroad tissue distribution, secreted and embedded
in basement membranes and implicated in the homeo-
stasis of type IV collagen.1 Peroxidasin uses bromide
ion (Br) and hydrogen peroxide (H2O2) to generate
hypobromous acid (HOBr), which is essential for for-
mation of sulfilimine (S¼N) bonds that covalently
crosslink type IV collagen molecules at the NC1-NC1
interface.2 Sulfilimine bonds crosslinking of a345(IV)
collagen in the glomerular basement membrane (GBM)
confer protection against Goodpasture (GP) disease, an
autoimmune kidney disease mediated by autoanti-
bodies binding to sites within the NC1 hexamers of
a345(IV) collagen.3 A recent study reports that
approximately 46% of patients with GP disease have
autoantibodies to peroxidasin, which inhibit HOBr
generation activity.4 Anti-peroxidasin antibodies,
additionally identified in approximately 13% of pa-
tients with anti-myeloperoxidase (anti-MPO) ANCA-
associated vasculitis (AAV), have been proposed to be
a serologic marker of disease in the pulmonary-renal
syndrome spectrum.4 Besides GP disease and AAV,
systemic lupus erythematosus (SLE) is another cause of
pulmonary-renal syndrome. We tested the hypothesis
that anti-peroxidasin antibodies are present in lupus
nephritis (LN).
RESULTS
Sera from 32 patients with biopsy-confirmed prolif-
erative or membranous LN (ISN/RPS class III, IV, or V)
were analyzed for peroxidasin immunoreactivity by
enzyme-linked immunosorbent assay (ELISA) (see
Supplementary Material). Anti-peroxidasin IgG
antibodies were identified in 2 of 25 (8%) patients
with proliferative LN (one each class III and class IV),
and also in 3 of 29 (10%) patients with GP disease
(Figure 1). The prevalence of anti-peroxidasin anti-
bodies in GP disease in our study is lower than that
previously reported (46%),4 which may be due to
demographic differences in the patient population.
Alternatively, our immunoassay may be less sensitive
owing to technical differences between the assays, in
which case the true prevalence of anti-peroxidasin an-
tibodies in LN may be underestimated. Anti-a3NC1 or
anti-MPO IgG autoantibodies, which invariably accom-
panied previously identified anti-peroxidasin antibodies,
are sometimes found in patients with LN,5,6 prompting
us to investigate whether these autoantibodies also
occurred together with anti-peroxidasin antibodies in
LN. However, in our LN cohort, none of the sera
contained antibodies binding to purified MPO
(Suppolementary Figure S1). Anti-a3NC1 antibodies
were also absent in LN, except for q case that did not
contain anti-peroxidasin antibodies (Supplementary
Figure S2). These findings imply that there are anti-
peroxidasin antibodies in a subpopulation of patients
with proliferative LN, in the absence of serologic
markers of anti-MPO AAV or GP disease.
We further characterized anti-peroxidasin anti-
bodies from LN compared with GP disease. Their
ability to bind native peroxidasin was verified by
competition ELISA using soluble antigen. Soluble per-
oxidasin inhibited antibody binding to immobilized
peroxidasin in a dose-dependent manner, with similar
half-maximal inhibitory concentration for LN and GP
sera (Figure 2a). To determine whether the autoanti-
bodies recognize conformational epitopes, we compared
1004 Kidney International Reports (2019) 4, 1004–1018
RESEARCH LETTERS
IgG binding with native versus misfolded peroxidasin.
Decreased binding to misfolded peroxidasin, indicative
of conformational epitopes, was observed for anti-
peroxidasin IgG from LN but not GP sera (Figure 2b).
DISCUSSION
Our results identify peroxidasin as a novel target of
autoantibodies in LN. In contrast to most autoantigens
implicated in SLE, peroxidasin is an intrinsic compo-
nent of basement membranes that provides a target for
direct autoantibody binding. Immunofluorescence
staining of the renal biopsy from the patient with LN
with higher titer of anti-peroxidasin showed strong
IgG staining (3þ) accompanied by IgA, C1q, C3, kappa,
and lambda (2–3þ each) in glomeruli, tubules, inter-
stitium, and vessels, with IgM (2þ) additionally found
in glomeruli and tubules. Antibodies binding to per-
oxidasin in the GBM may accelerate or exacerbate
glomerular immune complex formation, potentially
increasing disease activity or severity. Interestingly,
the patient with LN with higher titer of anti-
peroxidasin antibodies showed declining renal func-
tion (estimated glomerular filtration rate decreased from
96 ml/min per 1.73 m2 at serum collection to 52 ml/min
per 1.73 m2 at follow-up), but a larger sample size will
be required to analyze clinical associations.
Altered crosslinking of type IV collagen has been
proposed as a major pathogenic mechanism for anti-
peroxidasin autoantibodies from GP sera, based on
their ability to inhibit in vitro HOBr generation by
peroxidasin by 70%.4 Reduced crosslinking of a345(IV)
collagen in the GBM is essential for the pathogenesis of
GP disease because: (i) GP autoantibodies bind only to a
small subset of a345(IV)NC1 hexamers that are not sta-
bilized by crosslinks,7 and (ii) sulfilimine bonds lock the
epitopes preventing the in vivo binding of GP autoanti-
bodies to the GBM.8 Consistent with a role in promoting
GP disease, anti-peroxidasin immunoreactivity has been
detected before the onset of clinical disease in approxi-
mately half of the prediagnostic cases of GP disease.4
In analogous manner, continued presence of anti-
Figure 1. Anti-peroxidasin (anti-Pxdn) IgG autoantibodies are pre-
sent in sera of lupus nephritis. Immunoreactivity toward peroxidasin
was evaluated by enzyme-linked immunosorbent assay in sera from
controls (n ¼ 13) and patients with proliferative lupus nephritis
(class III or class IV), membranous lupus nephritis (class V), and
Goodpasture disease (GP). Sera diluted 1:100 were incubated in
wells coated with 200 ng purified recombinant peroxidasin, then IgG
binding was measured. The positivity threshold (indicated by a gray
line) was set at 3 SD above the mean of controls (dotted line). OD,
optical density.
Figure 2. Characterization of anti-peroxidasin (anti-Pxdn) antibodies.
(a) The specificity of antibodies for native peroxidasin was verified
by competition enzyme-linked immunosorbent assay using soluble
antigen. Lupus nephritis (LN) or Goodpasture disease (GP) sera
diluted 1:1000 were preincubated for 1 hour at room temperature
with the shown concentrations of native peroxidasin (Pxdn), then
added to wells coated with 50 ng of recombinant peroxidasin. For
each serum, IgG binding was calculated relative to binding in the
absence of an inhibitor, which was considered 100% (dotted refer-
ence line). Means and SD from 2 independent experiments are
shown. (b) Anti-Pxdn antibodies from LN sera recognize
conformation-dependent epitopes. A 1:100 dilution of sera containing
anti-Pxdn antibodies was applied to wells coated with 200 ng of
peroxidasin in phosphate-buffered saline (native Pxdn) or in 3M
guanidinium chloride containing 20 mM tris(2-carboxyethyl)phos-
phine as a reducing agent (misfolded Pxdn). The mean  SD of the
relative decrease in IgG binding to misfolded Pxdn was 34%  5%
for LN sera compared with 3%  5% for GP sera (P ¼ 0.012, 2-tailed
unpaired t test). OD, optical density.
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peroxidasin antibodies over a period of months
(commensurate with the rate of collagen IV turnover)
may impair the crosslinking of a345(IV) collagen in LN.
An association between LN and GP disease has been
reported in 1 retrospective study, in which 9% (14/157)
of patients with SLE had detectable levels of anti-GBM
(anti-a3NC1) autoantibodies along with antinuclear an-
tibodies, and some of these patients presented with
rapid progressive glomerulonephritis or were clinically
diagnosed with GP disease.6 It is plausible that anti-
peroxidasin antibodies may be among the factors
triggering GP disease in patients with LN, a rare pre-
sentation with worse outcomes.
To decrease sulfilimine bond formation, given that
already formed bonds are not affected, anti-peroxidasin
antibodies must be present when nascent collagen IV
molecules assemble within basement membranes. Their
impact would be maximal during periods of rapid
turnover of basement membranes, such as during fetal
development or the formation of feto-maternal inter-
face. Therefore, the potentially harmful role of anti-
peroxidasin autoantibodies in lupus pregnancies
warrants further investigation. As precedent, autoan-
tibodies to phospholipids or laminin-111 (a component
of basement membranes in placenta and developing
tissues) may occur in lupus and are associated with
adverse pregnancy outcomes, whereas maternal anti-
Ro/SS-A and anti-La/SS-B autoantibodies have been
implicated in neonatal lupus.9
Among limitations, this was an exploratory study in
a relatively small number of patients. Our findings
should be validated in a larger study, also investigating
clinical associations. Due to the small amounts of sera
available, we could not isolate sufficient IgG to test
whether anti-peroxidasin antibodies inhibit HOBr
generation. Definitive proof that anti-peroxidasin an-
tibodies are pathogenic will require future studies in
animal models yet to be developed.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
We thank Mary Hoffmann and Diane Salamon for spec-
imen and data procurement. This work was supported by a
pilot project (to Dorin-Bogdan Borza) from the Meharry
Translational Research Center grant U54 MD0007593 from
the National Institute on Minority Heath and Health Dis-
parities. The Kidney Translational Research Center at
Washington University School of Medicine was partly
supported by the George O’Brien Center for Kidney Dis-
ease Research (grant P30 DK079333) and by the Division of
Nephrology at Washington University School of Medicine.
Additional support was from the Paul Teschan Research
Fund grant from Dialysis Clinic Inc, R01 DK-116964 from
National Institute of Diabetes and Digestive and Kidney
Diseases, and the Burroughs Wellcome Fund Career
Award for Medical Scientists (13030995).
SUPPLEMENTARY MATERIAL
Figure S1. Absence of anti-MPO antibodies in sera of pa-
tients with LN.
Figure S2. Analysis of anti-a3NC1 antibodies in sera of
patients with LN.
Supplementary Methods.
Supplementary material is linked to the online version of
the paper at www.kireports.org.
REFERENCES
1. Bhave G, Cummings CF, Vanacore RM, et al. Peroxidasin
forms sulfilimine chemical bonds using hypohalous acids in
tissue genesis. Nat Chem Biol. 2012;8:784–790.
2. McCall AS, Cummings CF, Bhave G, et al. Bromine is an
essential trace element for assembly of collagen IV scaffolds in
tissue development and architecture. Cell. 2014;157:1380–
1392.
3. Pedchenko V, Bondar O, Fogo AB, et al. Molecular architecture
of the Goodpasture autoantigen in anti-GBM nephritis. N Engl
J Med. 2010;363:343–354.
4. McCall AS, Bhave G, Pedchenko V, et al. Inhibitory anti-
peroxidasin antibodies in pulmonary-renal syndromes. J Am
Soc Nephrol. 2018;29:2619–2625.
5. Turner-Stokes T, Wilson HR, Morreale M, et al. Positive anti-
neutrophil cytoplasmic antibody serology in patients with
lupus nephritis is associated with distinct histopathologic
features on renal biopsy. Kidney Int. 2017;92:1223–1231.
6. Li CH, Li YC, Xu PS, et al. Clinical significance of anti-
glomerular basement membrane antibodies in a cohort of
Chinese patients with lupus nephritis. Scand J Rheumatol.
2006;35:201–208.
7. Borza DB, Bondar O, Colon S, et al. Goodpasture autoanti-
bodies unmask cryptic epitopes by selectively dissociating
autoantigen complexes lacking structural reinforcement: novel
mechanisms for immune privilege and autoimmune patho-
genesis. J Biol Chem. 2005;280:27147–27154.
8. Luo W, Wang XP, Kashtan CE, et al. Alport alloantibodies but
not Goodpasture autoantibodies induce murine glomerulone-
phritis: protection by quinary crosslinks locking cryptic
alpha3(IV) collagen autoepitopes in vivo. J Immunol. 2010;185:
3520–3528.
9. Shoenfeld Y, Blank M. Autoantibodies associated with repro-
ductive failure. Lupus. 2004;13:643–648.
RESEARCH LETTERS
1006 Kidney International Reports (2019) 4, 1004–1018
